Reviewing PTC Therapeutics Inc. (PTCT)’s and Inovio Pharmaceuticals Inc. (NASDAQ:INO)’s results – MS Wkly

We will be contrasting the differences between PTC Therapeutics Inc. (NASDAQ:PTCT) and Inovio Pharmaceuticals Inc. (NASDAQ:INO) as far as dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 represents PTC Therapeutics Inc. (NASDAQ:PTCT) and Inovio Pharmaceuticals Inc. (NASDAQ:INO)s return on equity, return on assets and net margins.

Volatility and Risk

PTC Therapeutics Inc. is 74.00% more volatile than Standard & Poors 500 because the company has a beta of 1.74. Inovio Pharmaceuticals Inc. has a 2.01 beta and it is 101.00% more volatile than Standard & Poors 500.

Liquidity

PTC Therapeutics Inc.s Current Ratio and Quick Ratio are 3.3 and 3.2 respectively. The Current Ratio and Quick Ratio of its competitor Inovio Pharmaceuticals Inc. are 4.9 and 4.9 respectively. Inovio Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to PTC Therapeutics Inc.

Insider & Institutional Ownership

The shares of both PTC Therapeutics Inc. and Inovio Pharmaceuticals Inc. are owned by institutional investors at 85.61% and 44% respectively. 0.3% are PTC Therapeutics Inc.s share held by insiders. Comparatively, insiders own roughly 2.5% of Inovio Pharmaceuticals Inc.s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year PTC Therapeutics Inc. had bullish trend while Inovio Pharmaceuticals Inc. had bearish trend.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companys lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the companys product candidate in cancer stem cell program include PTC596, an orally bioavailable and potent small molecule, which has completed phase I clinical trials that targets tumor stem cell populations by reducing the activity and amount of a protein called BMI1. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The companys partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, Genentech, and U.S. Military HIV Research Program. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the article here:
Reviewing PTC Therapeutics Inc. (PTCT)'s and Inovio Pharmaceuticals Inc. (NASDAQ:INO)'s results - MS Wkly